Adagio Medical Holdings, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAdagio Medical Holdings, Inc. is a clinical-stage medical device company developing a proprietary ultra-low temperature catheter ablation platform to treat ventricular tachycardia, with no approved products or revenue.
What they do
Adagio Medical develops and seeks to commercialize the vCLAS Ventricular Ablation System and next-generation vCLAS Ultra, both based on its Ultra-Low Temperature Ablation (ULTA) platform for treating cardiac arrhythmias, primarily ventricular tachycardia (VT). The company has not generated revenue since 2023 and currently relies on funding for research and development and regulatory activities. Its focus is on securing FDA approval for the vCLAS System and advancing the vCLAS Ultra program.
Revenue drivers
- vCLAS Ventricular Ablation System — First-generation product candidate; received CE Mark in March 2024, but commercial activity in Europe has been paused and no revenue was recorded in Q2 2026.
- vCLAS Ultra Ventricular Ablation System — Next-generation catheter designed for faster, smaller, single-freeze ablations; received FDA IDE approval in April 2026, but is not yet commercialized.
- No commercial revenue — All recent quarterly revenue was zero; the company's previous revenue in 2023 was only $300,000, for the fiscal years ended December 31, 2023 and 2025.
Recent performance
For the quarter ended June 30, 2026, Adagio reported no revenue and a net loss of $6.7 million, or $(0.30) per basic share, compared to a net loss of $3.9 million in the year-ago quarter. Research and development expenses rose to $2.5 million from $2.0 million, while SG&A expenses were $2.5 million versus $2.4 million. As of June 30, 2026, cash and cash equivalents were $7.7 million, total assets were $33.9 million, total liabilities were $34.3 million, and shareholders' equity was negative $415,000. For fiscal year 2025, the company reported a net loss of $25.1 million and negative operating cash flow of $19.0 million. The company has not generated revenue in any quarter since at least September 2025.
Strategy
Adagio's stated strategy is to obtain FDA approval for its vCLAS Ventricular Ablation System and commercialize it in the U.S., supported by the FULCRUM-VT pivotal trial data. The company is also developing the vCLAS Ultra system, which is designed to improve usability and integrate with existing electrophysiology lab workflows. It plans to leverage its Breakthrough Device Designation and Expanded Access authorizations to gain early clinical experience. Management emphasizes the potential of its ULTA platform to address a large underserved VT patient population.
Risks
- No revenue and negative equity — The company has recorded zero revenue in recent quarters, has negative shareholders' equity of $415,000, and may need additional capital to continue operations.
- Regulatory approval uncertainty — The vCLAS System has only received CE Mark and Breakthrough Device Designation; PMA approval from the FDA is pending and not assured.
- Pivotal trial safety concerns — FULCRUM-VT trial reported a 2.4% major adverse event rate, including four peri-procedural deaths, one of which was adjudicated as definitely device-related.
- Nasdaq listing risk — The company received a delisting notice or listing-rule failure notice in June 2026, which could affect liquidity and investor confidence.
Outlook
Management indicated that the Q2 2026 milestones—including first vCLAS Ultra patient treatment and PMA submission for vCLAS—were an inflection point. The company expects to continue executing on regulatory and clinical milestones to bring the technology to market. However, given the cash position and negative equity, near-term funding will likely be necessary to support operations through approval and commercialization.